Zheng ZG, Cheng HM, Zhou YP, Zhu ST, Thu PM, Li HJ, Li P, Xu X

Osteoporosis develops because of impaired bone formation and/or excessive bone resorption. Several pharmacological treatment of osteoporosis has been developed; however, new treatments are still necessary. Cholesterol and estrogen receptor-related receptor alpha (ERR?) promote osteoclasts formation, survival, and cellular fusion and thus become high risk factors of osteoporosis. In this study, ...

Read More

we identified that carnosic acid (CA) suppressed bone loss by dual-targeting of sterol regulatory element-binding protein 2 (SREBP2, a major regulator that regulates cholesterol synthesis) and ERR?. Mechanistically, CA reduced nuclear localization of mature SREBP2 and suppressed de novo biogenesis of cholesterol. CA subsequently decreased the interaction between ERR? and peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC1?), resulting in decreased the transcription activity of ERR? and its target genes expression. Meanwhile, CA directly bound to the ligand-binding domain of ERR? and significantly promoted its ubiquitination and proteasomal degradation. Subsequently, STUB1 was identified as the E3 ligase of ERR?. The lysine residues (K51 and K68) are essential for ubiquitination and proteasomal degradation of ERR? by CA. In conclusion, CA dually targets SREBP2 and ERR?, thus inhibits the RANKL-induced osteoclast formation and improves OVX-induced bone loss. CA may serve as a lead compound for pharmacological control of osteoporosis.

Date: Jul. 01, 2020

View in: Pubmed Google Scholar

223392